These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
873 related articles for article (PubMed ID: 28263210)
1. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210 [TBL] [Abstract][Full Text] [Related]
2. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [TBL] [Abstract][Full Text] [Related]
3. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520 [TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Iagaru A; Mittra E; Dick DW; Gambhir SS Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of bone-seeking novel radiotracer Passah A; Tripathi M; Ballal S; Yadav MP; Kumar R; Roesch F; Meckel M; Sarathi Chakraborty P; Bal C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):41-49. PubMed ID: 27455986 [TBL] [Abstract][Full Text] [Related]
6. Prospective Study of Serial Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233 [TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906 [TBL] [Abstract][Full Text] [Related]
9. [Superiority of 18F-FNa PET/CT for Detecting Bone Metastases in Comparison with Other Diagnostic Imaging Modalities]. Lapa P; Saraiva T; Silva R; Marques M; Costa G; Lima JP Acta Med Port; 2017 Jan; 30(1):53-60. PubMed ID: 28501038 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[ Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756 [TBL] [Abstract][Full Text] [Related]
11. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989 [TBL] [Abstract][Full Text] [Related]
13. Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. Sampath SC; Sampath SC; Mosci C; Lutz AM; Willmann JK; Mittra ES; Gambhir SS; Iagaru A Clin Nucl Med; 2015 Mar; 40(3):e173-7. PubMed ID: 25140557 [TBL] [Abstract][Full Text] [Related]
14. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer. Simoncic U; Perlman S; Liu G; Jeraj R Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490 [TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806 [TBL] [Abstract][Full Text] [Related]
16. Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma. Broos WAM; van der Zant FM; Wondergem M; Knol RJJ Nucl Med Commun; 2018 Apr; 39(4):325-333. PubMed ID: 29351123 [TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients. Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990 [TBL] [Abstract][Full Text] [Related]
18. Comparison of [ Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246 [TBL] [Abstract][Full Text] [Related]
19. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [ Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455 [TBL] [Abstract][Full Text] [Related]
20. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]